Unnatural Products, a US-based biotech firm developing orally delivered macrocyclic peptides for previously intractable drug targets, has secured US$45 million in Series B financing led by The Venture Collective. High-profile participants include argenx, alongside existing backers such as the Merck Global Health Innovation Fund, Artis Ventures, Droia Ventures, and First Spark Ventures. The capital injection will accelerate development of its in-house drug discovery platform and move multiple macrocyclic peptide candidates into clinical stages, positioning the firm at the frontier of treating diseases once deemed “undruggable.” This injection underscores concentrated sovereign and strategic capital flowing into next-generation biopharmaceutical platforms, a trend now filtering into Middle East innovation clusters, where sovereign wealth vehicles are increasingly allocating to disruptive life sciences.
The strength of the syndicate, notably the presence of multinational pharmas and targeted healthcare funds, signals investor confidence in cutting-edge biologics with global market potential. As MENA governments continue to diversify economies and push pharma and biotech up the industrial agenda, capital allocation is pivoting toward foreign biotech partnerships, licensing deals, and anchor R&D hubs within the Gulf. This deal’s architecture—anchored by corporate ventures and cross-border institutions—serves as a template for how high-growth life sciences platforms gain traction in markets flush with capital but traditionally less involved in earlier-stage biotech. The funding also reinforces an emerging structure where pharmaceuticals are wired directly to sovereign portfolio goals, especially in post-oil economic transformation strategies.
Legal counsel from Latham & Watkins—led by Alex Kassai in the Bay Area—provided comprehensive transaction support, including guidance on data privacy from Jennifer Howes in San Diego and San Francisco. For the MENA region, the deeper implication is the replication of such biotech financing ecosystems, with jurisdictions including Abu Dhabi and Saudi Arabia actively setting up similar legal and commercial frameworks to attract comparable R&D firepower. Should Unnatural Products advance successfully, its IP and platform could gain licensing traction with Gulf ventures or anchor lucrative joint ventures with regional sovereign entities, further intertwining MENA capital with globally competitive drug discovery.
